Tailoring to RB: tumour suppressor status and therapeutic response.
The retinoblastoma tumour suppressor (RB) is a crucial regulator of cell-cycle progression that is invoked in response to a myriad of anti-mitogenic signals. It has been hypothesized that perturbations of the RB pathway confer a synonymous proliferative advantage to tumour cells; however, recent findings demonstrate context-specific outcomes associated with such lesions. Particularly, loss of RB function is associated with differential response to wide-ranging therapeutic agents. Thus, the status of this tumour suppressor may be particularly informative in directing treatment regimens.
Knudsen
Erik S
ES
Department of Cancer Biology, Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, Pennsylvania 19107, USA. eknudsen@kimmelcancercenter.org
Knudsen
Karen E
KE
D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000032:analysis; D002453:Cell Cycle; D016923:Cell Death; D050684:E2F Transcription Factors / Q000378:metabolism; D015972:Gene Expression Regulation, Neoplastic; D016147:Genes, Tumor Suppressor; D006801:Humans; D051379:Mice; D009369:Neoplasms / Q000378:metabolism* / Q000628:therapy; D009376:Neoplasms, Hormone-Dependent / Q000235:genetics; D009928:Organ Specificity; D047428:Protein Kinase Inhibitors / Q000494:pharmacology; D016160:Retinoblastoma Protein / Q000172:deficiency / Q000502:physiology*; D015398:Signal Transduction
D000970:Antineoplastic Agents; D015415:Biomarkers; D050684:E2F Transcription Factors; D047428:Protein Kinase Inhibitors; D016160:Retinoblastoma Protein